
Hakuna uthibitisho unaotaka kusadikiwa kuwa Samu Alimani, Mkurugenzi Mtendaji wa OpenAI tangu 2019, anatumia metformin.
Madai haya hayajumuishwa katika rekodi za umma, kufichua afya, au ripoti iliyothibitishwa.
Taarifa za afya za Alimani zinabaki kuwa siri.
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.